Brokerages forecast that Apricus Biosciences Inc (NASDAQ:APRI) will announce earnings of ($0.13) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Apricus Biosciences’ earnings. Apricus Biosciences reported earnings per share of ($0.04) during the same quarter last year, which would suggest a negative year-over-year growth rate of 225%. The company is expected to issue its next quarterly earnings report on Monday, March 12th.
According to Zacks, analysts expect that Apricus Biosciences will report full-year earnings of ($0.60) per share for the current year, with EPS estimates ranging from ($0.92) to ($0.28). For the next year, analysts anticipate that the business will report earnings of $1.28 per share. Zacks’ earnings per share averages are an average based on a survey of research analysts that cover Apricus Biosciences.
Apricus Biosciences (NASDAQ:APRI) last posted its quarterly earnings results on Thursday, November 2nd. The company reported ($0.30) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.15) by ($0.15). During the same period last year, the company posted ($0.19) EPS.
A number of research firms have weighed in on APRI. Zacks Investment Research lowered shares of Apricus Biosciences from a “buy” rating to a “sell” rating in a research report on Tuesday, November 7th. HC Wainwright reiterated a “buy” rating and issued a $4.50 price target on shares of Apricus Biosciences in a research report on Friday, November 3rd.
Apricus Biosciences (APRI) opened at $2.31 on Friday. The firm has a market cap of $32.10, a P/E ratio of 3.98 and a beta of 0.43. Apricus Biosciences has a 12-month low of $0.86 and a 12-month high of $4.07.
Apricus Biosciences Company Profile
Apricus Biosciences, Inc is a pharmaceutical company, which develops pharmaceutical products. The Company primarily focuses on the development and commercialization of products and product candidates in the areas of urology and rheumatology. The Company’s drug delivery technology is a permeation enhancer called NexACT.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Apricus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apricus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.